JP2018522831A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522831A5 JP2018522831A5 JP2017562029A JP2017562029A JP2018522831A5 JP 2018522831 A5 JP2018522831 A5 JP 2018522831A5 JP 2017562029 A JP2017562029 A JP 2017562029A JP 2017562029 A JP2017562029 A JP 2017562029A JP 2018522831 A5 JP2018522831 A5 JP 2018522831A5
- Authority
- JP
- Japan
- Prior art keywords
- chemical entity
- ring
- ocf
- carbon atom
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000005829 chemical entities Chemical class 0.000 claims 19
- 229910052799 carbon Inorganic materials 0.000 claims 11
- 125000004432 carbon atom Chemical group C* 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 102000034527 Retinoid X Receptors Human genes 0.000 claims 2
- 108010038912 Retinoid X Receptors Proteins 0.000 claims 2
- 230000008485 antagonism Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562169107P | 2015-06-01 | 2015-06-01 | |
| US62/169,107 | 2015-06-01 | ||
| PCT/US2016/035098 WO2016196513A1 (en) | 2015-06-01 | 2016-05-31 | 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522831A JP2018522831A (ja) | 2018-08-16 |
| JP2018522831A5 true JP2018522831A5 (enExample) | 2019-07-04 |
| JP6876625B2 JP6876625B2 (ja) | 2021-05-26 |
Family
ID=57441824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017562029A Active JP6876625B2 (ja) | 2015-06-01 | 2016-05-31 | Ｎｒ２ｂｎｍｄａレセプターアンタゴニストとしての３，３−ジフルオロピペリジンカルバメート複素環式化合物 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10584127B2 (enExample) |
| EP (1) | EP3303323B1 (enExample) |
| JP (1) | JP6876625B2 (enExample) |
| KR (1) | KR102613179B1 (enExample) |
| CN (1) | CN107849010B (enExample) |
| AR (1) | AR104837A1 (enExample) |
| AU (1) | AU2016270677B2 (enExample) |
| BR (1) | BR112017025023B1 (enExample) |
| CA (1) | CA2987606C (enExample) |
| DK (1) | DK3303323T3 (enExample) |
| ES (1) | ES2784398T3 (enExample) |
| IL (1) | IL255937B (enExample) |
| MX (1) | MX380424B (enExample) |
| RU (1) | RU2735277C2 (enExample) |
| TW (1) | TWI721987B (enExample) |
| WO (1) | WO2016196513A1 (enExample) |
| ZA (1) | ZA201708006B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017002775A (es) | 2014-09-15 | 2017-08-10 | Rugen Holdings (Cayman) Ltd | Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b. |
| US10221182B2 (en) | 2015-02-04 | 2019-03-05 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists |
| CN107849010B (zh) | 2015-06-01 | 2021-11-09 | 卢郡控股(开曼)有限公司 | 作为nr2b nmda受体拮抗剂的3,3‐二氟哌啶氨基甲酸酯杂环化合物 |
| CN106986874B (zh) * | 2016-01-20 | 2019-09-24 | 西华大学 | (1H-吡唑[3,4-d]嘧啶)-4-氨基衍生物及其作为IDO抑制剂在药物制备中的用途 |
| US11000526B2 (en) | 2016-11-22 | 2021-05-11 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| MX2022013029A (es) | 2020-04-17 | 2023-01-16 | Honeybrains Llc | Composiciones y metodos para el tratamiento de trastornos neuropsiquiatricos. |
| CN117159541A (zh) * | 2023-09-20 | 2023-12-05 | 南华大学 | Nat10拮抗剂在制备预防和/或治疗癫痫的药物中的应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3717867A1 (de) | 1987-05-26 | 1988-12-15 | Schiepe Stapelautomaten Gmbh | Stapelvorrichtung |
| UA59341C2 (uk) | 1995-08-11 | 2003-09-15 | Пфайзер, Інк. | (1s,2s)-1-(4-гідроксифеніл)-2-(4-гідрокси-4-фенілпіперидин-1-іл)-1-пропанолметансульфонат тригідрат |
| GB9805977D0 (en) * | 1998-03-19 | 1998-05-20 | Silver Joshua D | Improvements in variable focus optical devices |
| US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| HU227197B1 (en) | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| DE60210944T3 (de) * | 2001-02-23 | 2015-07-23 | Merck Sharp & Dohme Corp. | N-substituierte nichtaryl-heterocyclische nmda/nr2b antagonisten |
| EP1648882B1 (en) * | 2003-06-04 | 2008-08-06 | Merck & Co., Inc. | 3-fluoro-piperidines as nmda/nr2b antagonists |
| US7592360B2 (en) | 2003-06-04 | 2009-09-22 | Merck & Co., Inc. | 3-fluoro-piperidines as NMDA/NR2B antagonists |
| WO2005102390A2 (en) | 2004-04-22 | 2005-11-03 | Pfizer Japan, Inc. | Combinations comprising alpha-2-delta ligands and nmda receptor antagonists |
| JP2008509139A (ja) | 2004-08-03 | 2008-03-27 | メルク エンド カムパニー インコーポレーテッド | １，３−二置換ヘテロアリールｎｍｄａ／ｎｒ２ｂ拮抗薬 |
| WO2006069287A1 (en) * | 2004-12-22 | 2006-06-29 | Merck & Co., Inc. | Process for making substituted piperidines |
| WO2006113471A2 (en) | 2005-04-19 | 2006-10-26 | Merck & Co., Inc. | N-alkyl-azacycloalkyl nmda/nr2b antagonists |
| WO2007061868A2 (en) | 2005-11-17 | 2007-05-31 | Trustees Of Tufts College | Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors |
| EP1988077A4 (en) | 2006-02-23 | 2009-09-02 | Shionogi & Co | NUCLEIC HETEROCYCLIC DERIVATIVES SUBSTITUTED BY CYCLIC GROUPS |
| DE602007012272D1 (de) | 2006-09-07 | 2011-03-10 | Merck Sharp & Dohme | Difluorierte piperidine zur behandlung von morbus alzheimer und verwandten leiden |
| WO2008077552A1 (en) * | 2006-12-27 | 2008-07-03 | Sanofi-Aventis | Substituted isoquinoline and isoquinolinone derivatives |
| BRPI0909378A2 (pt) | 2008-03-27 | 2015-10-06 | Evotec Neurosciences Gmbh | métodos para tratar distúrbios usando antagonista seletivo de nmda subtipo nr2b |
| US20100010565A1 (en) * | 2008-07-09 | 2010-01-14 | Samuel Victor Lichtenstein | Extended range wireless muscular and neural stimulation |
| WO2010015637A1 (en) | 2008-08-06 | 2010-02-11 | Novartis Ag | New antiviral modified nucleosides |
| US20130096115A1 (en) | 2009-12-28 | 2013-04-18 | Afraxis, Inc. | Methods for treating autism |
| PH12012502079A1 (en) * | 2010-04-16 | 2013-02-11 | Ac Immune Sa | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
| WO2011156640A2 (en) | 2010-06-09 | 2011-12-15 | Afraxis, Inc. | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS |
| EP2582374A4 (en) | 2010-06-16 | 2014-03-19 | Afraxis Holdings Inc | METHOD FOR TREATING NERVOUS ELEMENTS |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| WO2012123312A1 (en) * | 2011-03-11 | 2012-09-20 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
| DK2713722T3 (en) * | 2011-05-31 | 2017-07-03 | Celgene Int Ii Sarl | Newly known GLP-1 receptor stabilizers and modulators |
| AU2013251079B2 (en) * | 2012-04-20 | 2017-03-23 | Ucb Pharma S.A. | Methods for treating Parkinson's disease |
| AP2015008591A0 (en) * | 2012-12-11 | 2013-07-31 | Takeda Pharmaceutical | Heterocyclic compounds |
| CN105308049A (zh) | 2013-01-29 | 2016-02-03 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
| CA2929502A1 (en) * | 2013-11-06 | 2015-05-14 | Bristol-Myers Squibb Company | Substituted pyridine derivatives useful as gsk-3 inhibitors |
| US9221796B2 (en) * | 2014-01-09 | 2015-12-29 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
| RU2721948C2 (ru) | 2014-05-06 | 2020-05-25 | Нортвестерн Юниверсити | Комбинации соединений, модулирующих nmda-рецептор |
| EP3152213B1 (en) | 2014-06-04 | 2018-10-31 | Rugen Holdings (Cayman) Limited | Difluoroethylpyridine derivatives as nr2b nmda receptor antagonists |
| MX2017002775A (es) | 2014-09-15 | 2017-08-10 | Rugen Holdings (Cayman) Ltd | Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b. |
| US20180271869A1 (en) | 2014-09-22 | 2018-09-27 | Jie Liu | Treatment of anxiety disorders and autism spectrum disorders |
| WO2016100349A2 (en) | 2014-12-16 | 2016-06-23 | Rugen Holdings (Cayman) Limited | Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists |
| US10221182B2 (en) | 2015-02-04 | 2019-03-05 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists |
| CN107849010B (zh) | 2015-06-01 | 2021-11-09 | 卢郡控股(开曼)有限公司 | 作为nr2b nmda受体拮抗剂的3,3‐二氟哌啶氨基甲酸酯杂环化合物 |
| US11000526B2 (en) | 2016-11-22 | 2021-05-11 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
-
2016
- 2016-05-31 CN CN201680042502.8A patent/CN107849010B/zh active Active
- 2016-05-31 WO PCT/US2016/035098 patent/WO2016196513A1/en not_active Ceased
- 2016-05-31 ES ES16804257T patent/ES2784398T3/es active Active
- 2016-05-31 TW TW105117083A patent/TWI721987B/zh active
- 2016-05-31 EP EP16804257.0A patent/EP3303323B1/en active Active
- 2016-05-31 DK DK16804257.0T patent/DK3303323T3/da active
- 2016-05-31 BR BR112017025023-3A patent/BR112017025023B1/pt active IP Right Grant
- 2016-05-31 AU AU2016270677A patent/AU2016270677B2/en active Active
- 2016-05-31 AR ARP160101591A patent/AR104837A1/es unknown
- 2016-05-31 JP JP2017562029A patent/JP6876625B2/ja active Active
- 2016-05-31 RU RU2017142005A patent/RU2735277C2/ru active
- 2016-05-31 MX MX2017015370A patent/MX380424B/es unknown
- 2016-05-31 US US15/578,460 patent/US10584127B2/en active Active
- 2016-05-31 KR KR1020177037807A patent/KR102613179B1/ko active Active
- 2016-05-31 CA CA2987606A patent/CA2987606C/en active Active
-
2017
- 2017-11-24 ZA ZA2017/08006A patent/ZA201708006B/en unknown
- 2017-11-27 IL IL255937A patent/IL255937B/en active IP Right Grant
-
2018
- 2018-08-10 US US16/100,596 patent/US10294230B2/en active Active
-
2020
- 2020-03-05 US US16/810,258 patent/US11136328B2/en active Active
-
2021
- 2021-10-01 US US17/491,676 patent/US20220024937A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522831A5 (enExample) | ||
| RU2017142005A (ru) | 3,3-дифторпиперидинкарбаматные гетероциклические соединения в качестве антагонистов nr2b nmda-рецептора | |
| JP2020517711A5 (enExample) | ||
| JP2019522007A5 (enExample) | ||
| JP2020511547A5 (enExample) | ||
| JP2016179996A5 (enExample) | ||
| RU2009135080A (ru) | Имидазохинолины в качестве двойных ингибиторов липидкиназы и mtor | |
| RU96115142A (ru) | Производные 5-(2-имидазолиниламино)бензимидазола, их получение и применение в качестве агонистов альфа-2-адреноцепторов | |
| JP2018529650A5 (enExample) | ||
| JP2009538910A5 (enExample) | ||
| JP2020506951A5 (enExample) | ||
| JP2008531537A5 (enExample) | ||
| JP2021502387A5 (enExample) | ||
| JP2018515495A5 (enExample) | ||
| JP2016527217A5 (enExample) | ||
| JP2008523041A5 (enExample) | ||
| JP2013520473A5 (enExample) | ||
| JP2010523709A5 (enExample) | ||
| JP2005530811A5 (enExample) | ||
| JP2012508251A5 (enExample) | ||
| JP2020520957A5 (enExample) | ||
| JP2006501201A5 (enExample) | ||
| JP2018522861A5 (enExample) | ||
| JP2007522142A5 (enExample) | ||
| JP2020128426A5 (enExample) |